eligibility_summary
Eligibility: Solid tumors per cohort—Dose Escalation: ovarian (epithelial/primary peritoneal/fallopian tube), endometrial, cervical, NSCLC, TNBC, pancreatic, CRC. Dose Optimization: ovarian and endometrial. Dose Expansion: low‑grade serous ovarian, cervical, NSCLC, TNBC. Exclude: uncontrolled CNS mets, carcinomatous meningitis, active infections, corneal disease/transplant, unresolved toxicities, major CV disease, QTcF ≥470 ms, pneumonitis/ILD, pregnancy/breastfeeding.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
NCT06400472 evaluates LY4170156, a first-in-human antibody-drug conjugate (ADC) targeting folate receptor alpha (FRα). LY4170156 binds FRα on tumor cells, is internalized, and releases a cytotoxic payload to kill FRα-expressing cells. It’s tested alone and with: bevacizumab (anti-VEGF monoclonal antibody inhibiting angiogenesis), carboplatin (platinum DNA–crosslinking chemotherapy), and pembrolizumab (anti–PD-1 immune checkpoint inhibitor). An itraconazole arm assesses CYP3A-mediated drug–drug interactions. Target cells/pathways: FRα-positive tumor cells in ovarian, endometrial, cervical, NSCLC, TNBC, pancreatic, and colorectal cancers, VEGF/angiogenesis, PD-1/PD-L1 immune checkpoint, and DNA damage/crosslinking pathways.